



## Appointment of Non-Executive Chair

November 19, 2020

Slough, UK, and Richmond, VA, November 19, 2020 – The Board of Directors of Indivior PLC are pleased to announce the appointment of Graham Hetherington as Chair of the Board with immediate effect. Graham's appointment was approved by the Board and follows a succession process undertaken by the Nomination & Governance Committee and led by Lorna Parker, Chair of the Nomination & Governance Committee.

Graham joined the Board as a Non-Executive Director in November 2019 and was appointed a member of the Audit and Remuneration Committees; he was appointed Chair of the Audit Committee in March 2020. Graham was previously Chair of the Audit Committee of BTG plc from 2016 and Senior Independent Director from 2017 until its acquisition by Boston Scientific Corporation in August 2019. He was previously Chief Financial Officer of Shire PLC, a global pharmaceutical company from 2008 until 2014, Chief Financial Officer of Bacardi and Company during 2007 and Chief Financial Officer of Allied Domecq plc from 1999 to 2005. He is a Fellow of the Chartered Institute of Management Accountants.

Graham will step down as Chair of the Audit Committee. Daniel Tassé will remain the Senior Independent Director and will be appointed Chair of the Audit Committee, effective immediately. Daniel has been a member of the Audit Committee since the Company listed in 2014 and served as Chair of the Audit Committee between July 2019 and March 2020.

Graham will be appointed as a member of the Nomination & Governance Committee and will remain a member of the Audit and Remuneration Committees. The Board also intends to undertake a search to identify an additional independent Non-Executive Director with recent and relevant financial experience.

Comment by Graham Hetherington, Chair of the Board of Indivior PLC Indivior is at an important stage of its development. I am honoured to be appointed Chair of the Board at this time. Indivior is a pioneer in its field and I look forward to working with the Board and leadership team to realize SUBLOCADE®'s (buprenorphine extended-release) full potential and more broadly its important Vision on behalf of all stakeholders.

Comment by Daniel Tassé, Senior Independent Director We are pleased to announce that Graham Hetherington has been appointed Chair of the Board. Graham has a strong record of value creation including in specialty pharma. We look forward to his continued active participation and leveraging his deep strategic, operational and financial experience to achieve the Group's strategic priorities.

### About Indivior

Indivior is a global pharmaceutical company working to help change patients' lives by developing medicines to treat addiction and serious mental illnesses. Our vision is that all patients around the world will have access to evidence-based treatment for the chronic conditions and co-occurring disorders of addiction. Indivior is dedicated to transforming addiction from a global human crisis to a recognized and treated chronic disease.

Building on its global portfolio of opioid dependence treatments, Indivior has a pipeline of product candidates designed to both expand on its heritage in this category and potentially address other chronic conditions and co-occurring disorders of addiction, including alcohol use disorder. Headquartered in the United States in Richmond, VA, Indivior employs more than 700 individuals globally and its portfolio of products is available in over 40 countries worldwide. Visit [www.indivior.com](http://www.indivior.com) to learn more. Connect with Indivior on LinkedIn by visiting [www.linkedin.com/company/indivior](http://www.linkedin.com/company/indivior).

### Investor Contact:

Jason Thompson,  
Indivior Vice President,  
Investor Relations  
+1 804-402-7123  
[Jason.Thompson@indivior.com](mailto:Jason.Thompson@indivior.com)

### Media Contacts:

**UK:**  
Tulchan Communications  
+44 207-353-4200

**US:**  
IndiviorMediaContacts@indivior.com  
+1 804-594-0836